Letter
Medicine, General & Internal
Mohit Sodhi, Ramin Rezaeianzadeh, Abbas Kezouh, Mahyar Etminan
Summary: This study, based on database analysis, investigates the link between glucagon-like peptide 1 agonists (such as semaglutide, liraglutide) used for weight loss and gastrointestinal adverse events.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2023)
Review
Neurosciences
Xiao-Yu Liu, Ni Zhang, Sheng-Xiao Zhang, Ping Xu
Summary: There is a close relationship between Alzheimer's disease (AD) and type 2 diabetes mellitus (T2DM), with GLP-1 potentially playing a role in treating cognitive impairment.
EUROPEAN JOURNAL OF NEUROSCIENCE
(2021)
Review
Pharmacology & Pharmacy
Ben Jones
Summary: GLP-1 receptor agonists are effective treatments for type 2 diabetes by stimulating insulin release and promoting weight loss, but their main side effect is nausea. Recent studies suggest that biased GLP-1 agonists may achieve enhanced anti-hyperglycaemic efficacy by avoiding receptor desensitization and downregulation, particularly through reduced beta-arrestin recruitment, although more human data is needed for confirmation.
BRITISH JOURNAL OF PHARMACOLOGY
(2022)
Editorial Material
Cardiac & Cardiovascular Systems
Kosuke Sawami, Atsushi Tanaka, Koichi Node
Summary: Obesity is associated with metabolic disturbances and increased risk of obesity-related cardiovascular diseases. Current anti-obesity drugs have shown weight loss effects but have not demonstrated significant reduction in the risk of cardiovascular diseases. Recent research suggests glucagon-like peptide-1 receptor agonists as potential first-line anti-obesity agents for preventing obesity-related cardiovascular diseases.
CARDIOVASCULAR DIABETOLOGY
(2022)
Review
Cardiac & Cardiovascular Systems
Bruno Verges, Victor Aboyans, Denis Angoulvant, Pierre Boutouyrie, Bertrand Cariou, Fabien Hyafil, Kamel Mohammedi, Pierre Amarenco
Summary: This review summarizes the potential mechanisms by which glucagon-like peptide-1 receptor agonists (GLP-1RAs) provide stroke protection in patients with diabetes. GLP-1RAs show multiple anti-atherosclerotic effects and reduce traditional stroke risk factors. Additionally, GLP-1RAs demonstrate direct cerebral effects in animal stroke models, promoting neurogenesis and reducing infarct volume.
CARDIOVASCULAR DIABETOLOGY
(2022)
Article
Medicine, Research & Experimental
Chun Han, Yuqing Sun, Qimeng Yang, Feng Zhou, Xinyu Chen, Lintao Wu, Lidan Sun, Jing Han
Summary: The study identified a novel dual GLP-1R and GCGR agonist, which showed potential for treatment of diabetes and obesity by improving glucose control in vivo. The development of peptide 2c with balanced GLP-1R and GCGR activations and potent effects on glucose control suggests a promising new approach for antidiabetic and/or antiobesity drug development.
MOLECULAR PHARMACEUTICS
(2021)
Article
Medicine, Research & Experimental
Jong Han Lee
Summary: COVID-19 is caused by SARS-CoV-2 and often leads to cytokine storms and lung inflammation. GLP-1RAs may have anti-inflammatory effects and be suitable for PHA patients after COVID-19 infection.
MEDICAL HYPOTHESES
(2022)
Review
Endocrinology & Metabolism
Xiaohui Pan, Shibing Tao, Nanwei Tong
Summary: Neurotransmitters play a vital role in regulating glucose homeostasis in pancreatic islets, and dysfunction of neurotransmitter receptors is associated with the development of type 2 diabetes. Targeting different transmitter systems holds great potential in preventing and treating type 2 diabetes and other metabolic diseases.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Review
Pharmacology & Pharmacy
Baocheng Xie, Shichun Chen, Yongxiang Xu, Weichao Han, Runkai Hu, Minyi Chen, Yusheng Zhang, Shaobo Ding
Summary: Diabetes mellitus and osteoporosis are closely related, and GLP-1RAs may help in controlling blood sugar levels and promoting bone formation, but more research is needed to clarify their specific effects and mechanisms.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Endocrinology & Metabolism
Majid Mufaqam Syed-Abdul, Priska Stahel, Alyssa Zembroski, Lili Tian, Changting Xiao, Avital Nahmias, Ian Bookman, Kimberly K. Buhman, Gary F. Lewis
Summary: GLP-2 increases CM secretion without mobilizing CLDs in the intestine. Proteomic analysis identified potential proteins involved in GLP-2-mediated CM secretion. This suggests that GLP-2 enhances CM secretion through a different mechanism than glucose.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Review
Biochemistry & Molecular Biology
Maria Caterina Baccari, Maria Giuliana Vannucchi, Eglantina Idrizaj
Summary: This mini-review summarizes the literature on the control of gastrointestinal motility by GLP-2, the mechanism through which it occurs, and the physiological implications of these effects. A better understanding of the role of GLP-2 in gastrointestinal motor responses may be important for the development of new therapeutic approaches in gastrointestinal dysmotility.
CURRENT PROTEIN & PEPTIDE SCIENCE
(2022)
Review
Biochemistry & Molecular Biology
Yusuke Karasawa, Kanako Miyano, Masahiro Yamaguchi, Miki Nonaka, Keisuke Yamaguchi, Masako Iseki, Izumi Kawagoe, Yasuhito Uezono
Summary: Rubiscolin-6 is a naturally occurring opioid peptide derived from spinach leaves, which has been shown to have beneficial effects via the central nervous system. Its unique advantage is its oral availability, making it a promising candidate for the development of a novel and safe drug.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Infectious Diseases
Xiuting Hu, Wei Cheng, Shengxian Fan, Yuhua Huang, Xi Chen, Zhiwei Jiang, Jian Wang
Summary: The study confirmed bacterial and fungal dysbiosis in type 2 SBS rats, and GLP-2 partially ameliorated these microbiota dysbiosis.
BMC INFECTIOUS DISEASES
(2021)
Article
Chemistry, Medicinal
Francis S. Willard, David B. Wainscott, Aaron D. Showalter, Cynthia Stutsman, Wenzhen Ma, Guemalli R. Cardona, Richard W. Zink, Christopher M. Corkins, Qi Chen, Nathan Yumibe, Javier Agejas, Graham R. Cumming, Jose Miguel Minguez, Alma Jimenez, Ana Mateo, Ana M. Castano, Daniel A. Briere, Kyle W. Sloop, Ana B. Bueno
Summary: LSN3318839 is a positive allosteric modulator of the glucagon-like peptide-1 receptor (GLP-1R), enhancing the activity of weak metabolite GLP-1(9-36)NH2 and full-length ligand GLP-1(7-36)NH2 through G protein-coupled signaling. Experiments show that the combination of LSN3318839 and GLP-1(9-36)NH2 produces insulin secretion and glucose lowering effects similar to GLP-1(7-36)NH2.
JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Article
Cardiac & Cardiovascular Systems
Ahmed M. Shaman, Stephen C. Bain, George L. Bakris, John B. Buse, Thomas Idorn, Kenneth W. Mahaffey, Johannes F. E. Mann, Michael A. Nauck, Soren Rasmussen, Peter Rossing, Benjamin Wolthers, Bernard Zinman, Vlado Perkovic
Summary: The study assessed the impact of semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes, showing significant kidney-protective effects with these medications and more pronounced effects in patients with preexisting chronic kidney disease.
Review
Pharmacology & Pharmacy
Pamela J. Hornby
EXPERT OPINION ON DRUG DISCOVERY
(2015)
Review
Gastroenterology & Hepatology
Anders Lehmann, Pamela J. Hornby
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
(2016)
Article
Pharmacology & Pharmacy
Amanda L. Kauffman, Alexandra V. Gyurdieva, John R. Mabus, Chrissa Ferguson, Zhengyin Yan, Pamela J. Hornby
FRONTIERS IN PHARMACOLOGY
(2013)
Article
Chemistry, Medicinal
HJ Breslin, CZ Cai, TA Miskowski, SV Coutinho, SP Zhang, P Hornby, W He
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
(2006)
Review
Pharmacology & Pharmacy
PJ Hornby, SM Prouty
BRITISH JOURNAL OF PHARMACOLOGY
(2004)
Article
Gastroenterology & Hepatology
PJ Hornby, TP Abrahams, ER Partosoedarso
GASTROENTEROLOGY CLINICS OF NORTH AMERICA
(2002)
Article
Medicine, General & Internal
PJ Hornby
AMERICAN JOURNAL OF MEDICINE
(2001)
Meeting Abstract
Gastroenterology & Hepatology
ER Partosoedarso, RT Scullion, TP Abrahams, PJ Hornby
Meeting Abstract
Gastroenterology & Hepatology
PJ Hornby, CM McDermott, V Sethi
Article
Pharmacology & Pharmacy
Edward S. Kimball, Nathaniel H. Wallace, Craig R. Schneider, Michael R. D'Andrea, Pamela J. Hornby
FRONTIERS IN PHARMACOLOGY
(2010)